Menu
Recruiting NCT05956236

Hip Prospective Study

Observational Hip Arthropathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Hip Arthropathy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Hip Prospective Study: Long-term Post-market Clinical Follow-up on the Use of SERF Hip Prostheses

Overview

In an evaluation report dated 2014, the HAS (Haute Autorité de Santé -French National Authority for Health) highlights that long-term clinical data on hip prostheses are needed in the context of the French healthcare system. In addition, per the European Regulation 2017/745, medical devices manufacturers shall conduct Post-Market Clinical Follow-up (PMCF) on their devices or provide a justification why PMCF is not applicable. Therefore, as part of the PMCF process of their hip prostheses, SERF wants to conduct a PMCF investigation to ensure the long-term real-life performance, safety and benefits of these prostheses. HiPS is a non-comparative, prospective, multicentric, national, 15-year follow-up clinical investigation.

Primary outcome measures

  • Survival rate [Time frame: Per operative period to 15 years]
Secondary outcome measures (11)
  • Intermediate survival rates [Time frame: Per operative period to 10 years]
  • Functional improvement [Time frame: Per operative period to 15 years]
  • Functional improvement [Time frame: Per operative period to 15 years]
  • Functional improvement [Time frame: Per operative period to 15 years]
  • Functional improvement [Time frame: Per operative period to 15 years]
  • Leg length discrepancy [Time frame: Pre operative period to 15 years]
  • Patient's Pain [Time frame: Pre operative period to 15 years]
  • Patient's quality of life [Time frame: Pre operative period to 15 years]
  • Patient's satisfaction [Time frame: Post operative period to 15 years]
  • Surgeon's satisfaction [Time frame: Per operative period to 15 years]
  • Adverse events [Time frame: Per operative period to 15 years]

Eligibility criteria

Inclusion criteria

  • Male or female adults
  • Planned to be implanted with investigational medical devices per the IFUs:
  • Implantation in skeletally mature adults (usually aged 60-65 and over), with an extremely painful and/or disabled joint and insufficiently improved by alternative treatment options after an observation period lasting from a few weeks to a few months
  • Implantation of investigational medical devices as integrated systems (all components from SERF, no component from another manufacturer)
  • For an intended purpose and indication listed in the IFUs
  • Affiliated to French social security
  • Who provided a dated and signed informed consent form

Exclusion criteria

  • Patient protected by a French legal measure
  • Patient not able to express his/her consent as deemed by the investigator
  • Patient deprived of liberty or hospitalized without consent
  • Pregnant or breastfeeding women
  • Patient contraindicated to investigational medical devices implantation per the IFUs
  • Patient contraindicated to radiographic follow-up
  • Patient a priori not able to meet the follow-up visits as deemed by the investigator
  • Patient not able to fulfil a self-assessment questionnaire as deemed by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • CHU St Etienne — Saint-Priest-en-Jarez

Identifiers

NCT: NCT05956236 · HiPS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗